Ferlazzo B, Barrile A, Bonanno D, Quattrocchi P, Santoro D, Savica V, Bellinghieri G
Allergologia e Immunologia Clinica, Policlinico Universitario, Messina.
Recenti Prog Med. 1998 Sep;89(9):434-7.
Increased anticardiolipin antibodies (aCL) serum levels have been recently described in haemodialysis patients and in renal transplant recipients, with a prevalence ranging from 4.8 to 46.4%. The causes and the clinical significance of aCL positivity in these patients are uncertain. We measured IgG- and IgM-aCL serum levels in 61 haemodialysis patients, in 14 renal transplant recipients and in 38 healthy controls. Increased levels of IgG-aCL were found in 4 haemodialysis patients (6.55%), in 2 transplant patients (14%) and in 2 of the healthy controls (5.26%). IgM-aCL serum levels were normal in all the patients. After one year of follow-up, no vascular events have been observed in aCL positive patients. It is probable that the presence of aCL in the serum of patients with end-stage renal disease is only an epiphenomenon and does not play a pathogenetic role.
近期研究表明，血液透析患者和肾移植受者血清中抗心磷脂抗体（aCL）水平升高，患病率在4.8%至46.4%之间。这些患者中aCL阳性的原因及临床意义尚不确定。我们检测了61例血液透析患者、14例肾移植受者和38例健康对照者的IgG-aCL和IgM-aCL血清水平。4例血液透析患者（6.55%）、2例移植患者（14%）和2例健康对照者（5.26%）的IgG-aCL水平升高。所有患者的IgM-aCL血清水平均正常。随访一年后，aCL阳性患者未观察到血管事件。终末期肾病患者血清中aCL的存在可能只是一种附带现象，不具有致病作用。
